AKCA earnings call for the period ending December 31, 2018.
News & Analysis: Akcea Therapeutics, Inc.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
A surprise rejection is a major setback for both partners, but not the end of the line.
The FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.
But the real opportunity may be with Ionis Pharmaceuticals.
Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.
An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.
Key events will make May a month to remember or forget for these fledgling drugmakers.
Can these sizzling biotech stocks keep the momentum going?
News of a major transaction between these two companies sends their stock prices in opposite directions.